Your story is true for all sorts of small investor
Post# of 15624
As many here know, I've been in ImmunoGen practically since it became public. Today it's sitting near 52 week lows, but I still believe in the drug that's in Phase 3 Trial, as well as the new technology drugs that should have their first trial results reported at ASH. With just a little success, I believe it should be priced comparable to SGEN, a large multiple of today's market cap. I actually think that if SGEN doesn't gain another drug approval before IMGN does, it could exceed SGEN, but we're talking about 2020 or later.
Gary